McKesson Designated by CMS as 2022 Qualified Clinical Data Registry
Retrieved on:
Tuesday, February 8, 2022
Software, Practice Management, Networks, Pharmaceutical, Oncology, Health, Data Management, Technology, EHR, Centers for Medicare & Medicaid Services, Medicare, Human Rights Campaign, Science, COVID-19, Vaccination, Cancer, Technology, Patient, GPO, Pharmacy, Center, The Network, Quality, Health, Organization, CMS, McKesson Corporation, Network, Physician, FORTUNE, Education, MD, MIPS, Pharmaceutical industry, Medical device, Medicine, Hospital, United, McKesson Corporation, Ontada, The US Oncology Network, MCKESSON CORPORATION, ONTADA, THE US ONCOLOGY NETWORK
For the sixth consecutive year, McKesson has received approval from The Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System (MIPS) as a Qualified Clinical Data Registry (QCDR).
Key Points:
- For the sixth consecutive year, McKesson has received approval from The Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System (MIPS) as a Qualified Clinical Data Registry (QCDR).
- The designation enables iKnowMed electronic health record (EHR) users to efficiently submit data directly to CMS without engaging a separate registry vendor, streamlining data submission and minimizing administrative burden.
- Seven custom QCDR measures identified by physician leaders in The US Oncology Network and submitted by McKesson were approved by CMS.
- Ontada is an oncology real-world data and evidence, clinical education and provider technology business dedicated to transforming the fight against cancer.